This company listing is no longer active
Kintor Pharmaceutical Future Growth
Future criteria checks 2/6
Kintor Pharmaceutical is forecast to grow earnings and revenue by 4% and 126.1% per annum respectively. EPS is expected to grow by 6.4% per annum. Return on equity is forecast to be -47.4% in 3 years.
Key information
4.0%
Earnings growth rate
6.4%
EPS growth rate
| Biotechs earnings growth | 42.3% |
| Revenue growth rate | 126.1% |
| Future return on equity | -47.4% |
| Analyst coverage | Low |
| Last updated | 14 Dec 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 388 | -615 | -597 | -1,016 | 1 |
| 12/31/2024 | 103 | -800 | -824 | -1,145 | 1 |
| 12/31/2023 | N/A | -841 | -1,319 | -1,202 | 1 |
| 6/30/2023 | N/A | -648 | -484 | -467 | N/A |
| 3/31/2023 | N/A | -801 | -736 | -714 | N/A |
| 12/31/2022 | N/A | -954 | -989 | -961 | N/A |
| 9/30/2022 | 17 | -995 | -1,192 | -1,144 | N/A |
| 6/30/2022 | 34 | -1,035 | -1,396 | -1,328 | N/A |
| 3/31/2022 | 34 | -938 | -1,276 | -1,190 | N/A |
| 12/31/2021 | 34 | -842 | -1,157 | -1,051 | N/A |
| 9/30/2021 | 17 | -740 | -960 | -851 | N/A |
| 6/30/2021 | N/A | -639 | -763 | -650 | N/A |
| 3/31/2021 | N/A | -573 | -620 | -516 | N/A |
| 12/31/2020 | N/A | -508 | -477 | -381 | N/A |
| 9/30/2020 | N/A | -419 | -430 | -341 | N/A |
| 6/30/2020 | N/A | -330 | -382 | -301 | N/A |
| 3/31/2020 | N/A | -281 | -342 | -264 | N/A |
| 12/31/2019 | N/A | -233 | -302 | -228 | N/A |
| 12/31/2018 | 1 | -108 | -134 | -115 | N/A |
| 12/31/2017 | 0 | -46 | -57 | -45 | N/A |
| 9/30/2017 | 0 | -41 | -43 | -36 | N/A |
| 6/30/2017 | 0 | -35 | -30 | -27 | N/A |
| 3/31/2017 | 1 | -45 | N/A | -21 | N/A |
| 12/31/2016 | 1 | -54 | N/A | -15 | N/A |
| 12/31/2015 | N/A | -11 | N/A | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9939 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 9939 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 9939 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 9939's revenue (126.1% per year) is forecast to grow faster than the Hong Kong market (8.1% per year).
High Growth Revenue: 9939's revenue (126.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 9939 is forecast to be unprofitable in 3 years.